Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVID200 in advanced solid tumors
NCT03834662Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2019
- Primary completion
- Feb 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, open-label trial of AVID200 in solid tumor (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Incidence of Treatment-Emergent Adverse Events up to 24 months. Started Jan 2019; status: completed.
02
Drugs
AVID200
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03834662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03834662.